Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH-762 in Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma
NCT06014086Phase 1Completed
- Sponsor
- Phio Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PH-762 in squamous cell carcinoma (SCC), melanoma and Merkel cell carcinoma (MCC), sponsored by Phio Pharmaceuticals. Primary endpoint: Adverse Events at 16 weeks. Started Nov 2023; status: completed.
02
Drugs
PH-762
03
Conditions
squamous cell carcinoma (SCC)melanomaMerkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT06014086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014086.